在部分转移性激素敏感性前列腺癌患者中是否有机会降低治疗强度？
Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
作者信息
Gómez-Aparicio María Antonia, López-Campos Fernando, Buchser David, Lazo Antonio, Willisch Patricia, Ocanto Abrahams, Sargos Paul, Shelan Mohamed, Couñago Felipe
机构信息
Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain.
Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
出版信息
Cancers (Basel). 2024 Jun 26;16(13):2331. doi: 10.3390/cancers16132331.
Abstract
The treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.
摘要
转移性激素敏感性前列腺癌的治疗格局不断演变，全身治疗是当前治疗的主要手段。人们已经对肿瘤体积和疾病表现等预后和预测因素进行了研究，以评估对不同治疗的反应。强化和降阶梯策略引起了极大关注，因此正在开展多项试验，以进一步使这些人群的治疗个性化。对于某些特征良好的选定患者，是否存在最佳治疗顺序以及减强化治疗的可能选择？这一问题及其他目标将是本综述的主题。
相似文献
1
Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?在部分转移性激素敏感性前列腺癌患者中是否有机会降低治疗强度？
Cancers (Basel). 2024 Jun 26;16(13):2331. doi: 10.3390/cancers16132331.
2
Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review.新诊断的转移性激素敏感性前列腺癌的当前治疗选择——一篇叙述性综述
Transl Androl Urol. 2021 Oct;10(10):3918-3930. doi: 10.21037/tau-20-1118.
3
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.转移性激素敏感型前列腺癌与联合治疗结局：综述。
JAMA Oncol. 2024 Jun 1;10(6):807-820. doi: 10.1001/jamaoncol.2024.0591.
4
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.转移性激素敏感前列腺癌系统治疗的未来方向。
World J Urol. 2023 Aug;41(8):2021-2031. doi: 10.1007/s00345-022-04135-8. Epub 2022 Aug 27.
5
The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌迅速演变的治疗格局
Clin Med Insights Oncol. 2024 Sep 19;18:11795549241277181. doi: 10.1177/11795549241277181. eCollection 2024.
6
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?转移性激素敏感型前列腺癌强化全身治疗的成本效益：三联疗法是否具有成本效益？
Eur Urol Oncol. 2024 Aug;7(4):870-876. doi: 10.1016/j.euo.2023.11.013. Epub 2023 Dec 6.
7
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.转移性去势敏感前列腺癌的现行全身治疗。
Curr Oncol Rep. 2024 May;26(5):488-495. doi: 10.1007/s11912-024-01509-6. Epub 2024 Apr 9.
8
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效：系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
9
Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer.激素强化治疗应在转移性前列腺癌的低风险阶段开始。
Eur Urol Open Sci. 2022 Sep 28;45:38-40. doi: 10.1016/j.euros.2022.05.015. eCollection 2022 Nov.
10
Systemic therapy in metastatic hormone-sensitive prostate cancer.转移性激素敏感前列腺癌的系统治疗。
Curr Opin Support Palliat Care. 2022 Dec 1;16(4):234-239. doi: 10.1097/SPC.0000000000000622. Epub 2022 Oct 13.
本文引用的文献
1
EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors.欧洲癌症研究与治疗组织2238号“降阶梯”试验：一项在新型雄激素受体通路抑制剂时代重新审视间歇性雄激素剥夺疗法的实用性试验。
Front Oncol. 2024 May 8;14:1391825. doi: 10.3389/fonc.2024.1391825. eCollection 2024.
2
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).PRESTO：雄激素阻断强化治疗高危生化复发去势敏感性前列腺癌患者的 III 期、开放标签研究（AFT-19）
J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23.
3
The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.东部肿瘤协作组体能状态对转移性前列腺癌患者总生存期的预后价值：一项系统评价和荟萃分析
Front Oncol. 2023 Dec 15;13:1194718. doi: 10.3389/fonc.2023.1194718. eCollection 2023.
4
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
5
Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.血清睾酮对转移性去势敏感性前列腺癌预后的影响：系统评价和荟萃分析。
Curr Opin Urol. 2023 Nov 1;33(6):472-481. doi: 10.1097/MOU.0000000000001132. Epub 2023 Sep 25.
6
Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.根据内脏转移部位对转移性前列腺癌患者进行总生存分析
Clin Genitourin Cancer. 2024 Apr;22(2):47-55.e2. doi: 10.1016/j.clgc.2023.08.004. Epub 2023 Aug 11.
7
Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.预后营养指数在转移性激素敏感性前列腺癌患者中的临床应用：一项回顾性、多中心、队列研究。
Prostate. 2023 Dec;83(16):1610-1618. doi: 10.1002/pros.24619. Epub 2023 Sep 10.
8
Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.识别预测性基因组生物标志物，以指导同步低容量转移性去势敏感前列腺癌的前列腺定向治疗。
Eur Urol Oncol. 2024 Apr;7(2):241-247. doi: 10.1016/j.euo.2023.07.014. Epub 2023 Aug 8.
9
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.真实世界中接受强化雄激素剥夺治疗（联合多西他赛或雄激素受体通路抑制剂）但未能达到最佳 PSA 缓解的转移性激素敏感性前列腺癌患者的生存结局。
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):279-282. doi: 10.1038/s41391-023-00696-w. Epub 2023 Jul 17.
10
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.哪些转移性激素敏感性前列腺癌患者从多西他赛治疗中获益：来自随机试验的个体参与者数据的系统评价和荟萃分析。
Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9.
Zotero 插件